Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors
James J. Crawford(Genesys (United States)), Joachim Rudolph, Ignacio Aliagas(Health and Functional Exposomics), Jonathan Cheong(Health and Functional Exposomics), Ning Liu, Weiru Wang(Guangzhou Institute of Geochemistry), Lionel Rougé(Novartis (Switzerland)), Simon Mathieu(Boston Biomedical Research Institute), Yanzhou Liu(Hebei University), Lesley Murray(Leeds Teaching Hospitals NHS Trust), Robert Mintzer(Health and Functional Exposomics), Peter W. Fan, Sreemathy Ramaswamy(Health and Functional Exposomics), Wendy Lee, Wei Zhou(Broad Institute), Hank La(Health and Functional Exposomics), Christopher E. Heise, Qi Chao(Shanghai Zhangjiang Laboratory), Klaus P. Hoeflich(Pivot)
Cited by 42
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
|Nature Genetics|2014|359
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
|Proceedings of the National Academy of Sciences|2009|255
Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires <i>cis-trans</i> receptor clustering
|Proceedings of the National Academy of Sciences|2012|213